îæ€çŽ¢
îæ€çŽ¢
î
Johnson & Johnson
JNJ244.120USD
-0.320-0.13%
çµå€Â 04/01, 16:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
670.29Bæ䟡ç·é¡
21.93çŽè¿12ã¶æPER
î
詳现æ å ± Johnson & Johnson äŒæ¥å
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Companyâs segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
Johnson & Johnsonã®äŒæ¥æ å ±
îäŒæ¥ã³ãŒãJNJ
äŒç€ŸåJohnson & Johnson
äžå Žæ¥Oct 31, 2080
æé«çµå¶è²¬ä»»è
ãCEOãDuato (Joaquin Boix)
åŸæ¥å¡æ°138100
蚌åžçš®é¡Ordinary Share
決ç®ææ«Oct 31
æ¬ç€Ÿæåšå°One Johnson & Johnson Plaza
éœåžNEW BRUNSWICK
蚌åžååŒæNASDAQ OMX NASDAQ Basic NYSE
åœUnited States of America
éµäŸ¿çªå·08933
é»è©±çªå·17325242455
ãŠã§ããµã€ãhttps://www.jnj.com/
äŒæ¥ã³ãŒãJNJ
äžå Žæ¥Oct 31, 2080
æé«çµå¶è²¬ä»»è
ãCEOãDuato (Joaquin Boix)
Johnson & Johnsonã®çµå¶é£
îäŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Mr. Joaquin Boix Duato
Mr. Joaquin Boix Duato
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
356.30K
+22.28%
Ms. Jennifer L. Taubert
Ms. Jennifer L. Taubert
Executive Vice President, Worldwide Chairman, Innovative Medicine
Executive Vice President, Worldwide Chairman, Innovative Medicine
194.45K
+8.45%
Ms. Kathryn E. Wengel
Ms. Kathryn E. Wengel
Executive Vice President, Chief Technology Officer and Risk Officer
Executive Vice President, Chief Technology Officer and Risk Officer
114.63K
+17.45%
Mr. Joseph J. Wolk
Mr. Joseph J. Wolk
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
85.01K
+0.07%
Ms. Elizabeth (Liz) Forminard
Ms. Elizabeth (Liz) Forminard
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
23.57K
+45.46%
Ms. Vanessa Broadhurst
Ms. Vanessa Broadhurst
Executive Vice President - Global Corporate Affairs
Executive Vice President - Global Corporate Affairs
23.00K
-2.57%
Ms. Kristen Mulholland
Ms. Kristen Mulholland
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
19.83K
+28.80%
Prof. Dr. John C. Reed, M.D., Ph.D.
Prof. Dr. John C. Reed, M.D., Ph.D.
Executive Vice President - Innovative Medicine, Research and Development
Executive Vice President - Innovative Medicine, Research and Development
10.66K
--
Mr. Hubert Joly
Mr. Hubert Joly
Independent Director
Independent Director
5.00K
--
Ms. Marillyn A. Hewson
Ms. Marillyn A. Hewson
Lead Independent Director
Lead Independent Director
3.00K
--
詳现ãèŠã
äŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Mr. Joaquin Boix Duato
Mr. Joaquin Boix Duato
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
356.30K
+22.28%
Ms. Jennifer L. Taubert
Ms. Jennifer L. Taubert
Executive Vice President, Worldwide Chairman, Innovative Medicine
Executive Vice President, Worldwide Chairman, Innovative Medicine
194.45K
+8.45%
Ms. Kathryn E. Wengel
Ms. Kathryn E. Wengel
Executive Vice President, Chief Technology Officer and Risk Officer
Executive Vice President, Chief Technology Officer and Risk Officer
114.63K
+17.45%
Mr. Joseph J. Wolk
Mr. Joseph J. Wolk
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
85.01K
+0.07%
Ms. Elizabeth (Liz) Forminard
Ms. Elizabeth (Liz) Forminard
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
23.57K
+45.46%
Ms. Vanessa Broadhurst
Ms. Vanessa Broadhurst
Executive Vice President - Global Corporate Affairs
Executive Vice President - Global Corporate Affairs
23.00K
-2.57%
åçå èš³
é貚: USDæŽæ°æå»: Tue, Jan 6
é貚: USDæŽæ°æå»: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
äºæ¥å¥USD
äŒç€Ÿå
åç
æ¯ç
Oncology-DARZALEX
3.67B
15.30%
Immunology-STELARA
1.57B
6.54%
Immunology-TREMFYA
1.42B
5.94%
Cardiovascular-ELECTROPHYSIOLOGY
1.42B
5.91%
Surgery-General
1.38B
5.74%
ä»ã®
14.53B
60.56%
å°åå¥USD
äŒç€Ÿå
åç
æ¯ç
United States
13.71B
57.13%
Europe
5.44B
22.67%
Asia-Pacific, Africa
3.61B
15.06%
Western Hemisphere, excluding U.S.
1.23B
5.13%
äºæ¥å¥
å°åå¥
äºæ¥å¥USD
äŒç€Ÿå
åç
æ¯ç
Oncology-DARZALEX
3.67B
15.30%
Immunology-STELARA
1.57B
6.54%
Immunology-TREMFYA
1.42B
5.94%
Cardiovascular-ELECTROPHYSIOLOGY
1.42B
5.91%
Surgery-General
1.38B
5.74%
ä»ã®
14.53B
60.56%
æ ªäž»
æŽæ°æå»: Thu, Feb 19
æŽæ°æå»: Thu, Feb 19
æ ªäž»çµ±èš
çš®é¡
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
The Vanguard Group, Inc.
10.11%
State Street Investment Management (US)
5.56%
BlackRock Institutional Trust Company, N.A.
5.44%
Geode Capital Management, L.L.C.
2.41%
JP Morgan Asset Management
1.65%
ä»ã®
74.84%
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
The Vanguard Group, Inc.
10.11%
State Street Investment Management (US)
5.56%
BlackRock Institutional Trust Company, N.A.
5.44%
Geode Capital Management, L.L.C.
2.41%
JP Morgan Asset Management
1.65%
ä»ã®
74.84%
çš®é¡
æ ªäž»çµ±èš
æ¯ç
Investment Advisor
40.54%
Investment Advisor/Hedge Fund
23.84%
Research Firm
3.15%
Pension Fund
2.26%
Bank and Trust
2.10%
Insurance Company
1.62%
Sovereign Wealth Fund
1.48%
Hedge Fund
0.61%
Family Office
0.09%
ä»ã®
24.32%
æ©é¢æè³å®¶ä¿ææ ª
îæŽæ°æå»: Thu, Jan 1
æŽæ°æå»: Thu, Jan 1
å ±åæé
æ©é¢æè³å®¶æ°
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
2025Q4
6038
1.81B
75.24%
+5.09M
2025Q3
5885
1.79B
74.44%
+16.50K
2025Q2
5920
1.78B
73.89%
-7.65M
2025Q1
6002
1.80B
74.62%
+4.60M
2024Q4
5953
1.78B
74.14%
+8.28M
2024Q3
5699
1.77B
73.47%
+2.69M
2024Q2
5691
1.75B
72.75%
+9.12M
2024Q1
5685
1.73B
71.58%
-6.08M
2023Q4
5686
1.72B
71.40%
-7.80M
2023Q3
5524
1.72B
71.21%
-159.24M
詳现ãèŠã
æ ªäž»åå
îäŒç€Ÿå
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
å€åç
æ¥ä»
The Vanguard Group, Inc.
243.46M
10.11%
+4.18M
+1.75%
Jan 30, 2026
State Street Investment Management (US)
133.87M
5.56%
+1.66M
+1.26%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
130.93M
5.44%
+1.51M
+1.17%
Dec 31, 2025
Geode Capital Management, L.L.C.
57.95M
2.41%
+1.74M
+3.09%
Dec 31, 2025
JP Morgan Asset Management
39.68M
1.65%
+3.08M
+8.41%
Dec 31, 2025
State Farm Insurance Companies
34.11M
1.42%
--
--
Dec 31, 2025
Norges Bank Investment Management (NBIM)
33.46M
1.39%
+1.53M
+4.79%
Dec 31, 2025
Morgan Stanley Smith Barney LLC
23.96M
0.99%
-1.30M
-5.14%
Dec 31, 2025
Wellington Management Company, LLP
23.24M
0.96%
-2.59M
-10.04%
Dec 31, 2025
BlackRock Asset Management Ireland Limited
21.42M
0.89%
+492.72K
+2.35%
Dec 31, 2025
詳现ãèŠã
é¢é£ETF
îæŽæ°æå»: Sat, Dec 6
æŽæ°æå»: Sat, Dec 6
éæå
æ¯ç
iShares U.S. Pharmaceuticals ETF
23.7%
VanEck Pharmaceutical ETF
10.06%
FT Vest DJIA Dogs 10 Target Income ETF
9.82%
Health Care Select Sector SPDR Fund
9.32%
Proshares Ultra Health Care
9%
iShares U.S. Healthcare ETF
8.9%
JPMorgan Healthcare Leaders ETF
8.38%
First Trust NASDAQ Pharmaceuticals ETF
8.28%
Fidelity MSCI Health Care Index ETF
7.67%
Franklin Income Focus ETF
7.08%
詳现ãèŠã
iShares U.S. Pharmaceuticals ETF
æ¯ç23.7%
VanEck Pharmaceutical ETF
æ¯ç10.06%
FT Vest DJIA Dogs 10 Target Income ETF
æ¯ç9.82%
Health Care Select Sector SPDR Fund
æ¯ç9.32%
Proshares Ultra Health Care
æ¯ç9%
iShares U.S. Healthcare ETF
æ¯ç8.9%
JPMorgan Healthcare Leaders ETF
æ¯ç8.38%
First Trust NASDAQ Pharmaceuticals ETF
æ¯ç8.28%
Fidelity MSCI Health Care Index ETF
æ¯ç7.67%
Franklin Income Focus ETF
æ¯ç7.08%
é åœé
îéå»5幎éã®é
åœéç·æ¯æé¡ã¯
46.31B
ç±³ãã«ã§ããã
æ¥ä»
é
åœé
æš©å©ç¢ºå®æ¥
æ¯ææ¥
é
åœèœã¡æ¥
Jan 02, 2026
JNJ.NB Final Cash Dividend of gross USD 1.3 paid on Mar 10, 2026 going ex on Feb 24, 2026
Feb 24, 2026
Mar 10, 2026
Feb 24, 2026
Jan 02, 2025
JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Mar 04, 2025 going ex on Feb 18, 2025
Feb 18, 2025
Mar 04, 2025
Feb 18, 2025
Oct 15, 2024
JNJ.NB Final Cash Dividend of gross USD 1.24 paid on Dec 10, 2024 going ex on Nov 26, 2024
Nov 26, 2024
Dec 10, 2024
Nov 26, 2024
Jul 17, 2024
JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Sep 10, 2024 going ex on Aug 27, 2024
Aug 27, 2024
Sep 10, 2024
Aug 27, 2024
Apr 16, 2024
JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Jun 04, 2024 going ex on May 20, 2024
May 21, 2024
Jun 04, 2024
May 20, 2024
Jan 02, 2024
JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Mar 05, 2024 going ex on Feb 16, 2024
Feb 20, 2024
Mar 05, 2024
Feb 16, 2024
Oct 19, 2023
JNJ.NB Final Cash Dividend of gross USD 1.19 paid on Dec 05, 2023 going ex on Nov 20, 2023
Nov 21, 2023
Dec 05, 2023
Nov 20, 2023
Jul 20, 2023
JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Sep 07, 2023 going ex on Aug 25, 2023
Aug 28, 2023
Sep 07, 2023
Aug 25, 2023
Apr 18, 2023
JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Jun 06, 2023 going ex on May 22, 2023
May 23, 2023
Jun 06, 2023
May 22, 2023
Jan 03, 2023
JNJ.NB Interim Cash Dividend of gross USD 1.13 paid on Mar 07, 2023 going ex on Feb 17, 2023
Feb 21, 2023
Mar 07, 2023
Feb 17, 2023
詳现ãèŠã
æ ªåŒåå²
îæ¥ä»
é
åœèœã¡æ¥
çš®é¡
æ¯ç
ããŒã¿ãªã
æ¥ä»
é
åœèœã¡æ¥
çš®é¡
æ¯ç
ããŒã¿ãªã
